ABCL
AbCellera Biologics Inc. Common Shares
After-Market
13.78
AbCellera Biologics Inc. Common Shares Profile
About
Info & Links
CEO
Carl L. G. Hansen
Headquarters
VANCOUVER, A1 V5Y 1G6, CANADA
Industry
Sector
Website
Auditor
KPMG LLP
Share holders
88
Employees
562
AbCellera Biologics Inc. Common Shares Statistics
Valuation Measures
Market Capitalization2
4.46B
Enterprise Value
4.32B
Enterprise Value/EBITDA(ttm)
-22.43
Price to Earnings Ratio(ttm)
--
Price to Sales(ttm)
63.66
Price to Book(mrq)
4.68
Price to Cash(ytd)
--
Profitability
Gross Margin(ttm)
100.00%
Operating Margin(ttm)
-248.83%
Profit Margin(ttm)
-636.37%
Return on Equity(ttm)
-17.49%
Return on Invested Capital(ttm)
-17.64%
Return on Assets(ttm)
-12.36%
Income Statement
Revenue(ttm)
66.17M
Revenue Per Share(ttm)
0.22
Gross Profit(ttm)
66.17M
EBITDA(ttm)3
-192.56M
Net Income Available to Common(ttm)
-164.66M
Diluted EPS(ttm)
-0.54
Share Statistics
Beta (5Y Monthly)
1.41
52-Week Change
130.54%
S&P 500 52-Week Change
19.75%
S&P 500 Member
No
Stock Optionable
Yes
Total Shares Outstanding1
306.61M
Dividend Yield
0.00%
Float4
219.53M
% Held by Insiders
28.40%
% Held by Institutions
61.42%
Balance Sheet
Total Cash(mrq)
565.10M
Total Cash Per Share(mrq)
1.84
Total Debt(mrq)
0.00
Total Debt/Equity(mrq)
0.00%
Current Ratio(mrq)
12.77%
Quick Ratio(mrq)
12.77%
Book Value Per Share(mrq)
2.92
Cash Flow
Operating Cash Flow Per Share(ytd)
-0.02
Free Cash Flow(ytd)
-13.56M
Table Key
mrq = Most Recent Quarter
ttm = Trailing Twelve Months
ytd = Year To Date
Footnotes
Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.
- 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
- 2 Market Cap is calculated using total shares outstanding and the most recent share price.
- 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
- 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.